TTY Biopharm Company Competitors
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside | Analysts | Market Cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | Outperform |
9
|
$149.85 | $174.55 | 13.45% | 3 | $360.64B |
| AZN | AstraZeneca PLC | Outperform |
17
|
£123.32 | £165.99 | 31.97% | 16 | £191.17B |
| NOVN | Novartis | Hold |
10
|
CHF90.54 | CHF105.00 | 18.86% | 9 | CHF184.74B |
| ABT | Abbott Laboratories | Outperform |
9
|
$104.67 | $118.92 | 20.86% | 7 | $182.09B |
| PFE | Pfizer | Outperform |
2
|
$28.18 | $32.87 | 8.23% | 6 | $159.68B |
| SAN | Sanofi | Outperform |
16
|
93.18€ | 102.80€ | 16.98% | 9 | 116.35€B |
| GSK | GSK | Outperform |
12
|
£17.81 | £17.30 | 9.49% | 12 | £72.61B |
| CSL | CSL | Outperform |
12
|
$277.05 | $205.51 | -26.67% | 5 | $133.89B |
| BAX | Baxter International Inc | Outperform |
17
|
$35.95 | $44.86 | 22.39% | 5 | $18.32B |
| 1093 | CSPC Pharmaceutical Group | Buy |
18
|
HK$6.76 | HK$9.50 | 37.57% | 6 | HK$80.07B |
| 4142 | Adimmune | - |
10
|
NT$31.05 | NT$55.00 | -100.00% | 0 | NT$14.08B |
| PSTV | Plus Therapeutics | Buy |
11
|
$2.24 | $11.00 | 569.64% | 2 | $9.71M |